Table 1:
Baseline and Time-varying Characteristics of Study Participants in TB-Confirmed Versus TB Unlikely, and TB-Unconfirmed Versus TB Unlikely Diagnostic Classification Groups
| Baseline Characteristics | Total | TB-Confirmed | TB-Unconfirmed | TB Unlikely | TB- Confirmed |
TB- Unconfirmed |
|---|---|---|---|---|---|---|
| N = 160 | N = 13¶ (8.1%) | N = 67# (41.9%) | N = 80** (50.0%) | P* | P* | |
| Median age at enrollment in months (IQR†) | 22.8 (10.0–62.7) | 48.5 (15.6–79.3) | 22.9 (14.4–60.9) | 22.7 (8.9–54.9) | 0.33 | 0.48 |
| No. of subjects in age categories (n, %) | ||||||
| 0 to < 12 mo | 42 (26.3%) | 2 (15.4%) | 14 (20.9%) | 26 (32.5%) | ||
| 12 mo to < 24 mo | 43 (26.9%) | 4 (30.8%) | 22 (32.8%) | 17 (21.3%) | 0.45 | 0.30 |
| 24 mo to < 60 mo | 34 (21.3%) | 2 (15.4%) | 14 (20.9%) | 18 (22.5%) | ||
| ≥60 mo | 41 (25.6%) | 5 (38.5%) | 17 (25.4%) | 19 (23.8%) | ||
| Gender (n, %) | ||||||
| Male | 87 (54.4%) | 9 (69.2%) | 35 (52.2%) | 43 (53.8%) | 0.37 | 0.87 |
| Female | 73 (456%) | 4 (30.8%) | 32 (47.8%) | 37 (46.3%) | ||
| Malaria status (n, %)‡ | ||||||
| Positive | 25 (N = 64, 39.1%) | 0/3 (0%) | 5/22 (22.7%) | 20/39 (51.3%) | 0.23 | 0.03 |
| Negative | 39 (N = 64, 60.9%) | 3/3 (100%) | 17/22 (77.3%) | 19/39 (48.7%) | ||
| Laboratory-based malaria diagnosis (n, %) | ||||||
| Positive | 15 (N = 59, 25.4%) | 0/3 (0%) | 2/20 (10.0%) | 13/36 (36.1%) | 0.54 | 0.06 |
| Negative | 44 (N = 59, 74.6%) | 3/3 (100%) | 18/20 (90.0%) | 23/36 (63.9%) | ||
| Baseline median CD4 count (IQR), n | 746 (315–1339), 159 | 438 (104–799), 13 | 722 (332–1339), 66 | 757 (391–1474), 80 | 0.07 | 0.77 |
| Baseline median CD4 percentage (IQR), n | 15.0 (9.0–22.5), 159 | 11.0 (6.0–15.0), 13 | 15.1 (9.0–20.2), 66 | 16.6 (9.7–24.3), 80 | 0.10 | 0.21 |
| Baseline median WAZ§ (IQR), n | −2.66 (−3.7 to −1.6), 154 | −3.31 (−4.9 to −1.7), 12 | −3.32 (−4.3 to −2.3), 65 | −2.01 (−3.1 to −1.1), 77 | 0.03 | <0.01 |
| Baseline median WHZ||(IOR), n | −1.67 (−3.0 to −0.2), 119 | −2.46 (−4.0 to −1.9), 8 | −2.49 (−3.7 to −1.1), 50 | −1.05 (−2.3–0.3), 61 | 0.01 | <0.01 |
| Time-Varying Characteristics |
Total | TB-Confirmed | TB-Unconfirmed | TB Unlikely | TB- Confirmed, P* |
TB- Unconfirmed, P* |
| Median CD4 count over the study period (IQR), n | 1003 (503–1694), 477 | 457 (104–998), 34 | 932 (474–1603), 199 | 1146 (606–1891), 244 | <0.01 | 0.02 |
| Median CD4 percentage over the study period (IQR), n | 19.1 (113–260), 476 | 15.0 (6.0–25.2), 34 | 18.2 (12.2–24.1), 199 | 20.1 (13.5–27.9), 243 | 0.01 | 0.01 |
| Median WAZ§ over the study period (IQR), n | −1.83 (−3.0 to −1.0), 1102 | −2.66 (−4.5 to −1.3), 70 | −2.34 (−3.4 to −1.4), 482 | −1.45 (−2.3 to −0.7), 550 | <0.01 | <0.01 |
| Median WHZ|| over ihe study period (IQR), n | −0.97 (−2.1–0.2), 805 | −2.24 (−3.5 to −0.8), 46 | −1.37 (−2.8 to −0.3), 341 | −0.48 (−1.5–06), 418 | <0.01 | <0.01 |
P values from Fisher exact test reported for categorical variables. Wilcoxon 2-sample test t approximation or Student t test P values reported for continuous variables. Reference group is TB Unlikely.
Interquartile range.
Positive malaria status defined as positive clinical or laboratory smear diagnosis of malaria at enrollment.
WAZ were based on WHO child growth standards.
WHZ were based on WHO child growth standards for children 5 years of age and younger.
In the confirmed TB group, 6 died and 1 was lost to follow-up.
In the unconfirmed TB group, 9 died and 8 were lost to follow-up.
In the unlikely TB group, 15 died and 4 were lost to follow-up.